The art and science of running a successful pharmaceutical company.
 | November 4, 2009
By:Bassil Dahiyat
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
 |
November 4, 2009
By:Walter Armstrong, Senior Editor
A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
|
November 4, 2009
By:George Koroneos, Online Content & News Editor
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
|
October 8, 2009
By:George Koroneos, Online Content & News Editor
Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.
|
October 7, 2009
By:George Koroneos, Online Content & News Editor
Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe?
|
 | October 1, 2009
By:Walter Armstrong
Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that?
|
September 30, 2009
By:George Koroneos, Online Content & News Editor
Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more.
|
September 14, 2009
By:George Koroneos, Online Content & News Editor
Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Conducting clinical trials in emerging regions can give you the edge. Five Quintiles experts share their insights into navigating the global regulatory landscape.